JOHNSON & JOHNSON (JNJ)
Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
📈 **POSITIVE** • High confidence analysis (83%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business